Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Finerenone

FDA-approved product (tablet, oral), marketed as Kerendia.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Finerenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Aldosterone antagonists
FDA pharmacologic class
Nonsteroidal Mineralocorticoid-Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Finerenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Finerenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial

    NCT07775482 · start 2027-01

    Registered record
    Registry ID
    NCT07775482
    Conditions
    Acute Kidney Injury; Renal Insufficiency,Chronic; Kidney Diseases
    Interventions
    Finerenone (BAY94-8862 ) 10 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-01
    Completion
    2030-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury; Renal Insufficiency,Chronic; Kidney Diseases
    InterventionFinerenone (BAY94-8862 ) 10 mg; Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Precision T1D Platform - New Therapies for Cardio-Renal Complications

    NCT07594145 · start 2026-11-01

    Registered record
    Registry ID
    NCT07594145
    Conditions
    Type 1 Diabetes; T1D Heart Failure; Cardio-renal Vascular Function and Failure; Diabetic Chronic Kidney Disease
    Interventions
    Finerenone; Sotagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2031-12-31
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes; T1D Heart Failure; Cardio-renal Vascular Function and Failure; Diabetic Chronic Kidney Disease
    InterventionFinerenone; Sotagliflozin
    PhasePhase 2
    Registry statusNot yet recruiting

  • Finerenone for Premature Ovarian Insufficiency (POI)

    NCT07815509 · start 2026-09-15

    Registered record
    Registry ID
    NCT07815509
    Conditions
    Premature Ovarian Insufficiency
    Interventions
    Finerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-15
    Completion
    2028-09
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremature Ovarian Insufficiency
    InterventionFinerenone; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

    NCT07605390 · start 2026-08

    Registered record
    Registry ID
    NCT07605390
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes
    Interventions
    Epic-Based Clinician Notification; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2028-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes
    InterventionEpic-Based Clinician Notification; Usual Care
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Finerenone for the Treatment of Type 2 Diabetes-Related Kidney Disease: Efficacy Observation and Related Factor Analysis

    NCT07717697 · start 2026-07-30

    Registered record
    Registry ID
    NCT07717697
    Conditions
    Type 2 Diabetes Mellitus; Diabetic Kidney Disease
    Interventions
    Finerenone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-07-30
    Completion
    2029-01-30
    Enrolment
    425

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Diabetic Kidney Disease
    InterventionFinerenone
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

    NCT07575672 · start 2026-07-01

    Registered record
    Registry ID
    NCT07575672
    Conditions
    HFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation); Finerenone
    Interventions
    Finerenone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2029-12-31
    Enrolment
    2,832

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHFpEF - Heart Failure With Preserved Ejection Fraction; TAVI(Transcatheter Aortic Valve Implantation); Finerenone
    InterventionFinerenone; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

    NCT07192952 · start 2026-06-01

    Registered record
    Registry ID
    NCT07192952
    Conditions
    Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    Interventions
    Finerenone (Kerendia, BAY94-8862)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-06-01
    Completion
    2030-12-30
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeft Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    InterventionFinerenone (Kerendia, BAY94-8862)
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

    NCT07397650 · start 2026-05-11

    Registered record
    Registry ID
    NCT07397650
    Conditions
    Acute Heart Failure
    Interventions
    Finerenone Oral Tablet; Finerenone Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-05-11
    Completion
    2028-09-30
    Enrolment
    550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Heart Failure
    InterventionFinerenone Oral Tablet; Finerenone Placebo
    PhasePhase 4
    Registry statusRecruiting

  • "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"

    NCT07598864 · start 2026-05-01

    Registered record
    Registry ID
    NCT07598864
    Conditions
    Diabetic Nephropathy
    Interventions
    Dapagliflozin +Finerenone arm; Dapagliflozin arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2027-05-01
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionDapagliflozin +Finerenone arm; Dapagliflozin arm
    PhasePhase 3
    Registry statusNot yet recruiting

  • Safety and Efficacy of Finerenone in Metabolic Dysfunction Associated Steatotic Liver Disease(MASLD/NAFLD) Related Cirrhosis Patients With Ascites in Prevention of Chronic Kidney Disease.

    NCT07585526 · start 2026-04-15

    Registered record
    Registry ID
    NCT07585526
    Conditions
    MASLD; Chronic Kidney Diseases
    Interventions
    Finerenone; Spironolactone; Standard Medical Treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-04-15
    Completion
    2028-03-31
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMASLD; Chronic Kidney Diseases
    InterventionFinerenone; Spironolactone; Standard Medical Treatment
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Rubix LS Diabetic Kidney Disease (DKD) Registry Study

    NCT07348718 · start 2025-12-15

    Registered record
    Registry ID
    NCT07348718
    Conditions
    Diabetic Kidney Disease (DKD)
    Interventions
    Kidney-Protective Therapies Used in Routine Care
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-12-15
    Completion
    2026-04-01
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Kidney Disease (DKD)
    InterventionKidney-Protective Therapies Used in Routine Care
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

    NCT07188805 · start 2025-11-19

    Registered record
    Registry ID
    NCT07188805
    Conditions
    Left Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    Interventions
    Finerenone (Kerendia, BAY94-8862); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-11-19
    Completion
    2029-12-30
    Enrolment
    111

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeft Ventricular Systolic Dysfunction; Heart Failure (Pediatric)
    InterventionFinerenone (Kerendia, BAY94-8862); Placebo
    PhasePhase 3
    Registry statusRecruiting

  • An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.

    NCT07124039 · start 2025-07-16

    Registered record
    Registry ID
    NCT07124039
    Conditions
    Chronic Kidney Disease; Type 2 Diabetes Mellitus
    Interventions
    Finerenone (Kerendia, BAY948862)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-07-16
    Completion
    2026-02-28
    Enrolment
    6,537

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Type 2 Diabetes Mellitus
    InterventionFinerenone (Kerendia, BAY948862)
    PhaseNot recorded
    Registry statusCompleted

  • Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

    NCT07315191 · start 2025-06-13

    Registered record
    Registry ID
    NCT07315191
    Conditions
    Henoch Schönlein Purpura Nephritis
    Interventions
    ACEI / ARB+finerenone; ACEI/ARB
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-06-13
    Completion
    2028-04-30
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHenoch Schönlein Purpura Nephritis
    InterventionACEI / ARB+finerenone; ACEI/ARB
    PhasePhase 4
    Registry statusRecruiting

  • Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

    NCT07056595 · start 2025-05-21

    Registered record
    Registry ID
    NCT07056595
    Conditions
    IgA Nephropathy (IgAN)
    Interventions
    Finerenone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-05-21
    Completion
    2026-05-21
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIgA Nephropathy (IgAN)
    InterventionFinerenone
    PhaseNot applicable
    Registry statusRecruiting